Cash Flow Statement (Annual)

BGB / Blackstone / GSO Strategic Credit Fund Cash Flow Statement shows changes in cash positions over time. Cash Flow Statement data includes Cash from Operating Activities (CFOP), Cash from Investing Activities, and Cash from Financing Activities.

All numbers are times 1,000 except per share units.

2009 2010 2011 2012 2013 2014 2015 2016 2017
Net Cash Provided By Used In Operating Activities Continuing Operations
  Profit Loss -2,390,696 -607,323 -268,453 829,882 2,892,919 3,695,553 1,624,350 2,249,648 3,373,954
  Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
    Net Realized Gains Losses On Investments Funds Related 135,243 -337,932 -540,353 -710,755 -1,792,106 -3,343,635 -4,121,003 -2,023,503 -4,613,531
    Unrealized Gain Loss On Investments - - - - - - -722,064 241,617 21,589
    Non Cash Performance Allocations - - - - - - - - -
    Non Cash Performance Allocations And Incentive Fee Compensation - - - - - - - - -
    Share Based Compensation 3,048,108 2,440,148 1,396,062 949,633 855,087 734,733 629,642 323,651 338,687
    Amortization Of Intangible Assets 158,048 162,051 207,591 139,174 95,671 101,915 101,437 82,943 46,776
    Other Noncash Income Expense -25,243 -20,591 -164,359 -353,052 -206,451 -121,808 -144,657 -16,711 -362,865
  Increase Decrease In Operating Capital
    Increase Decrease In Cash Acquired With Consolidation Of Fund Entity - - - - - - - - -
    Increase Decrease In Cash Of Discontinued Operations - -4,398 -110,607 -48,284 -173,726 -476,533 -442,370 - -33,566
    Increase Decrease In Accounts Receivable -35,050 108,162 -116,714 60,520 46,580 -229,331 213,706 -87,074 -282,026
    Increase Decrease In Receivables Under Repurchase Agreements - - - - -99,034 -148,984 204,893 -86,398 -118,495
    Increase Decrease Due From Affiliates -467,449 68,761 31,403 73,485 -237,169 -229,837 97,487 57,907 298,501
    Increase Decrease In Other Operating Assets -82,386 20,802 19,233 -51,031 -15,445 82,890 149,732 -99,108 -17,377
    Increase Decrease In Accrued Salaries -94,931 -101,377 -273,281 -119,862 -454,724 -836,852 -917,428 -572,814 -1,177,852
    Increase Decrease In Financial Instruments Sold Not Yet Purchased - - - - - - 96,780 42,761 -62,730
    Increase Decrease In Accounts Payable And Accrued Liabilities -987,241 12,535 -203,419 -408,256 -316,082 -305,978 -474,652 -214,651 -755,165
    Increase Decrease In Payables Under Repurchase Agreements - - - - - - 11,012 34,286 43,516
    Increase Decrease In Due To Affiliates -261,685 3,286 -3,439 -88,425 -216,671 35,504 -102,847 39,035 -9,652
    Decrease In Financial Instruments Used In Operating Activities - - - - - 10,979,850 7,937,114 8,798,358 19,573,150
    Increase In Financial Instruments Used In Operating Activities - - - - - 13,648,180 10,621,190 8,195,594 18,723,360
  Net Cash Provided By Used In Operating Activities Continuing Operations - - - 583,155 3,547,941 1,654,989 2,397,043 -541,286 -2,448,740
Net Cash Provided By Used In Investing Activities Continuing Operations
  Payments To Acquire Property Plant And Equipment 23,627 54,160 36,484 37,020 25,637 30,271 59,247 21,826 24,347
  Net Cash Provided By Used In Investing Activities Continuing Operations - - - -222,981 -165,904 -24,425 -53,404 -28,976 -188,208
Net Cash Provided By Used In Financing Activities Continuing Operations
  Payments Of Dividends Minority Interest 92,531 113,872 608,287 261,582 844,011 982,405 677,110 533,925 813,987
  Proceeds From Minority Shareholders 205,558 262,006 1,183,952 773,714 1,114,457 1,560,183 479,678 329,005 759,907
  Payments Of Tax Receivable Agreement - - - - - 86,733 84,484 78,985 135,831
  Net Settlement Of Vested Common Units And Repurchase Of Common And Partnership Units - - - - - - - - -
  Proceeds From Loans 593,989 415,828 13,301 633,742 11,367 491,150 2,423,614 3,321,081 7,600,153
  Repayments Of Long Term Debt 323,993 43,266 27,424 33,168 16,777 8,735 517,629 420,714 1,766,129
  Payments Of Capital Distribution - 599,390 702,832 614,530 1,469,479 2,348,596 3,497,346 2,018,669 2,842,582
  Net Cash Provided By Used In Financing Activities Continuing Operations - - - -405,411 -3,259,614 -1,049,907 -1,919,402 570,170 2,771,339
Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents - - - - - - - - -
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
  Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect - - - - - - - - -
  Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents - - - - - - - - -
Supplemental Cash Flow Information
  Interest Paid 5,097 3,554 81,407 80,159 125,361 116,296 126,167 151,948 160,178
  Income Taxes Paid 52,035 57,672 43,945 30,234 69,858 236,718 115,814 65,790 106,032
Noncash Or Part Noncash Acquisition Net Nonmonetary Assets Acquired Liabilities Assumed
  Non Cash Contributions From Non Controlling Interest Holders - - - 6,803 63,273 47,683 2,277 1,155 1,112
  Non Cash Distributions To Non Controlling Interest Holders - - - -6,803 18,537 60,589 -34 -13,536 -69,721
  Transfer Of Interests To Non Controlling Interest Holders 1,991 -21,996 2,614 -4,584 -2,403 -1,885 -12,272 -8,278 -6,016
  Change Of Parent Ownership Interest - -19,346 -5,893 -2,423 -2,519 9,032 92,785 7,881 -15,197
  Net Settlement Of Vested Common Units 199,447 198,739 186,644 167,046 153,522 69,426 139,941 101,898 127,392
  Conversion Of Stock Amount Issued1 -109,748 252,113 -228,722 256,239 43,255 117,877 131,883 77,520 59,334
  Deferred Tax Asset Exchange Of Founders And Senior Managing Directors Interests In Partnership Holdings -142,982 351,183 -300,471 204,320 113,757 105,686 195,291 59,304 74,487
  Due To Affiliates From Non Cash Financing Activities Exchange Of Related Parties - - - - 33,177 82,704 130,264 53,935 63,430
  Partners Capital Account Period Increase Decrease Exchange Of Related Parties - - - - 80,580 22,982 65,027 5,369 11,057
  Issuance Of Common Partners Units - - - - - - - - -

Peers - Investment Advice (6282)

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

11h - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

13h - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

CUSIP: 09257R101